Experienced in Splenic Neoplasm

Chung-pin R. Li

No. 155, Sec. 2, Li Nong Street, 112, 
Beitou, TPQ, TW 
Experienced in Splenic Neoplasm
No. 155, Sec. 2, Li Nong Street, 112, 
Beitou, TPQ, TW 
OverviewLocationsClinical Research

Overview

Chung-pin Li practices in Beitou, Taiwan. Li is rated as an Experienced expert by MediFind in the treatment of Splenic Neoplasm. Their top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Agranulocytosis, and Bullous Pemphigoid.

Their clinical research consists of co-authoring 134 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Splenic Neoplasm.

Locations

No. 155, Sec. 2, Li Nong Street, 112, Beitou, TPQ, Taiwan
Other Locations
No. 201, Sec. 2, Shih Pai Road, Taipei, TNQ 11217, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
View 1 Less Clinical Trial

134 Total Publications

Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience.
Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile